Skip to main content

Table 1 Patient Characteristics (n = 875)

From: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Age at diagnosis, median (range), years 56 (30–90)
Follow-up time, median (range), months 29 (1–115)
Menopausal status Postmenopausal 602 68.8 %
Premenopausal 273 31.2 %
Vital status Died 345 39.4 %
Alive 448 51.2 %
Censored 82 9.4 %
Family history Yes 230 26.3 %
No 643 73.7 %
CA125 level <500 U/ml 193 22.6 %
≥500 U/ml 662 77.4 %
Ascites No 99 11.3 %
<500 ml 146 16.7 %
≥500 ml 629 72.0 %
FIGO Stage Early (I, II) 75 8.6 %
Advanced (III, IV) 800 91.4 %
Cytoreduction R0 272 31.1 %
R1 434 49.6 %
R2 169 19.3 %
Chemosensitivity Yes 568 66.9 %
No 237 27.9 %
NA 44 5.2 %
Platelet count (median, IQR)(×109/L) 301 (235–383)
Thrombocytosis Yes 121 13.8 %
No 753 86.2 %
Fibrinogen level (median, IQR)(g/L) 3.85 (3.19–4.45)
Hyperfibrinogenemia Yes 332 45.9 %
No 392 54.1 %